Statement: On average cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density, whereas those in cohort 2 lost mineral density.
Primary_evidence: Outcome Measurement:    Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12   Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.   Time frame: 12 months Results 1:    Arm/Group Title: Denosumab 60 mg Q6M   Arm/Group Description: [Not Specified]   Overall Number of Participants Analyzed: 123   Least Squares Mean (95% Confidence Interval)   Unit of Measure: Percent Change from Baseline  4.8        (4.3 to 5.4) Results 2:    Arm/Group Title: Placebo   Arm/Group Description: [Not Specified]   Overall Number of Participants Analyzed: 122   Least Squares Mean (95% Confidence Interval)   Unit of Measure: Percent Change from Baseline  -.7        (-1.3 to -.1)